• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Augustinos Nicholas sold $517,906 worth of shares (6,290 units at $82.34) (SEC Form 4)

    6/17/25 5:33:16 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    AUGUSTINOS NICHOLAS

    (Last) (First) (Middle)
    6340 SEQUENCE DRIVE

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    DEXCOM INC [ DXCM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/13/2025 S 2,618(1) D $81.69 37,083 I by Trust(2)
    Common Stock 06/16/2025 S 3,672(1) D $82.8 33,411 I by Trust(2)
    Common Stock 5,046(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On March 14, 2025, Mr. Augustinos adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Augustinos. The shares set forth above were sold pursuant to the 10b5-1 Plan.
    2. Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the reporting person is a trustee.
    3. Included in this number are 5,046 unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ Jereme M. Sylvain, as Attorney-in-Fact for Nicholas Augustinos 06/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DXCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    7/26/2024$161.00 → $80.00Outperform → Neutral
    Robert W. Baird
    7/26/2024$145.00 → $75.00Overweight → Neutral
    JP Morgan
    5/30/2024$130.00Neutral
    Redburn Atlantic
    More analyst ratings

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Foletta Mark G sold $228,605 worth of shares (2,750 units at $83.13) (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      6/18/25 4:31:58 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Legal Officer Brown Michael Jon sold $41,400 worth of shares (500 units at $82.80), decreasing direct ownership by 0.52% to 95,102 units (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      6/18/25 4:31:27 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Director Augustinos Nicholas sold $517,906 worth of shares (6,290 units at $82.34) (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      6/17/25 5:33:16 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    SEC Filings

    See more
    • SEC Form SD filed by DexCom Inc.

      SD - DEXCOM INC (0001093557) (Filer)

      5/29/25 4:35:26 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • DexCom Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - DEXCOM INC (0001093557) (Filer)

      5/13/25 8:31:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Amendment: DexCom Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:20:31 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Dexcom with a new price target

      Truist initiated coverage of Dexcom with a rating of Buy and set a new price target of $102.00

      6/16/25 7:46:45 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Dexcom with a new price target

      Goldman initiated coverage of Dexcom with a rating of Buy and set a new price target of $104.00

      5/30/25 8:41:14 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Dexcom with a new price target

      Mizuho initiated coverage of Dexcom with a rating of Outperform and set a new price target of $85.00

      4/10/25 12:40:59 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care